…
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Palvella Therapeutics, Inc. is a publicly listed small biopharmaceutical company; public disclosures are limited and it appears focused on developing proprietary therapeutic candidates. Long-term growth may be driven by clinical development milestones, regulatory approvals, successful collaborations and access to financing, and investors may find potential upside from positive trial outcomes and licensing or partnership opportunities.
The most important investment risks include early-stage clinical and regulatory uncertainty, the need for ongoing financing with associated dilution risk, limited public disclosure about the pipeline and significant execution risk in commercialization.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics, Inc |
-2.56 1.76% |
143.21 | - | - | - | - |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.